| 摘要 |
<p>RNA-molecule having a sequence with a length of at least 10 nucleotides, which consist of one of the sequences of SEQ ID NO: 1 (a 143 base pair sequence fully defined in the specification), SEQ ID NO: 2 (a 228 base pair sequence fully defined in the specification), SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 or reverse, complementary or reverse-complementary sequences according to SEQ ID NO: 23 (a 227 base pair sequence fully defined in the specification), SEQ ID NO: 24 (a 242 base pair sequence fully defined in the specification), and SEQ ID NO: 7-22, is new. RNA-molecule having a sequence with a length of at least 10 nucleotides, which consist of one of the sequences of SEQ ID NO: 1 (a 143 base pair sequence fully defined in the specification), SEQ ID NO: 2 (a 228 base pair sequence fully defined in the specification), SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 or reverse, complementary or reverse-complementary sequences according to SEQ ID NO: 23 (a 227 base pair sequence fully defined in the specification), SEQ ID NO: 24 (a 242 base pair sequence fully defined in the specification) and SEQ ID NO: 7-22, where the sequences of SEQ ID NO: 7-22 and of SEQ ID NO: 3-6 are not defined, the RNA molecule has a virulence-associated function in Streptococcus sp. and/or an essential function for the growth of Streptococcus sp., is new. Independent claims are included for: (1)a polynucleotide molecule, preferably DNA-molecule coding for the RNA-molecule; (2)#an expression vector comprising the polynucleotide molecule, which is operably linked to at least one regulatory sequence; (3)#a host cell comprising the polynucleotide molecule and/or the expression vector; and (4)#use of a substance that is interacted with the RNA molecule, for producing a pharmaceutical composition for the treatment of infectious diseases in which Streptococcus sp., preferably Streptococcus pyogenes is involved. ACTIVITY : Antimicrobial. MECHANISM OF ACTION : None given.</p> |
